XBiotech Inc
4XB
Company Profile
Business description
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.
Contact
5217 Winnebago Lane
AustinTX78744
USAT: +1 512 386-2900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
88
Stocks News & Analysis
stocks
Chart of the Week: AI proving a threat to company moats
The latest insights on AI from our equity research team.
stocks
ASX coal miners will benefit from higher prices
Middle East conflict pushes coal prices higher.
stocks
Nvidia earnings: Another stellar quarter with no signs of a slowdown
We think Nvidia stock is moderately undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,847.70 | 14.20 | 0.16% |
| CAC 40 | 7,969.88 | 4.61 | -0.06% |
| DAX 40 | 23,502.25 | 228.67 | -0.96% |
| Dow JONES (US) | 46,199.62 | 793.64 | -1.69% |
| FTSE 100 | 10,305.29 | 98.31 | -0.94% |
| HKSE | 26,025.42 | 156.88 | 0.61% |
| NASDAQ | 22,164.37 | 315.16 | -1.40% |
| Nikkei 225 | 55,239.40 | 1,539.01 | 2.87% |
| NZX 50 Index | 13,194.16 | 121.44 | -0.91% |
| S&P 500 | 6,626.82 | 89.27 | -1.33% |
| S&P/ASX 200 | 8,640.60 | 14.40 | 0.17% |
| SSE Composite Index | 4,062.98 | 13.08 | 0.32% |